Rapid ID of Nosocomial Infections - GENSPEED® MRSA and C. Diff OneStep
Greiner Bio-One has developed the GENSPEED® Test System, a unique molecular diagnostics system that combines crude lysis of bacteria with multiplex-PCR before the final automated analysis of PCR-products in the new GENSPEED® R2 device.
For rapid detection of MRSA, the GENSPEED® MRSA Test running on the GENSPEED® Test System was developed. It is a DNA-based in-vitro diagnostic tool for qualitative detection of MRSA within 75 minutes from human nasal and pharyngeal smears, targeting both resistance genes mecA and mecC.
With the GENSPEED® C.Diff OneStep, toxigenic C. difficile can be rapidly identified by detecting genes for glutamate dehydrogenase (GDH), toxin A, toxin B and binary toxin in one step in less than 90 minutes. With this one-step procedure GENSPEED® C.Diff OneStep clearly outdates the sequential diagnostic procedure (two-step method according to ESCMID-guidelines) that uses at least two different test systems, e.g. a GDH antigen assay followed by a toxin assay. GENSPEED® C.Diff OneStep will be launched by the end of this year.
The GENSPEED® Test System in general scores points for speed and high sensitivity at a reasonable price. Analyses of individual samples are possible at any time. Three controls (for DNA amplification, hybridization, as well as a negative control) on the Test Chip offer great reliability. The compact and maintenance free system was designed for optimal ease of use. Pre-filled reagents and the automated GENSPEED® R2 device reduce the number of process steps to a minimum. GENSPEED® is an inexpensive solution that is already available on the market.
Tags: Clostridium difficile, MRSA, Multi-Drug Resistant Organisms
Date Published: November 17, 2014
Source article link: Greiner Bio-One GmbH » company contact details
ESwab’s Versatility And Efficacy To Detect MRSA From Nasal Swabs Shown
LiDia® BSI Test: Detection of Pathogens in Clinical Whole Blood Samples
FDA-Cleared Liofilchem MIC Test Strip (MTS™) Clindamycin (CD)
Bruker Acquires MERLIN Adding Speciality AST and ART